Another study on real-life VA outcomes in patients that receive anti-VEGF treatment for nAMD, diabetic macular edema, or branch retinal vein occlusion in Germany identified patient-associated non-adherence to treatment and follow-up regimens as a major factor limiting clinical treatment outcomes under real-world conditions [13]. The gene discussed is VEGFA; the disease is diabetic macular edema.